SurModics surges on Merck ophthalmic deal
This article was originally published in Clinica
Executive Summary
Drug-delivery products firm SurModics saw its share price soar around 19% this week, after announcing it had partnered with pharmaceutical giant Merck & Co in an ophthalmic licensing and research deal.
You may also be interested in...
Pipeline Watch: Five Approvals And 23 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Lack Of Industry Involvement In Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.